611 related articles for article (PubMed ID: 24061039)
41. Neoadjuvant therapy for gastric cancer.
Chadha MK; Kuvshinoff BW; Javle MM
Oncology (Williston Park); 2005 Aug; 19(9):1219-27; discussion 1227-8, 1231-2. PubMed ID: 16255136
[TBL] [Abstract][Full Text] [Related]
42. cMET as a potential therapeutic target in gastric cancer (Review).
Teng L; Lu J
Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
[TBL] [Abstract][Full Text] [Related]
43. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
Chen DH; Yu JW; Jiang BJ
World J Gastroenterol; 2015 Sep; 21(33):9707-16. PubMed ID: 26361417
[TBL] [Abstract][Full Text] [Related]
44. Recent developments in chemotherapy of advanced gastric cancer.
Götze T; Schütte K; Röcken C; Malfertheiner P; Ebert MP
Dig Dis; 2004; 22(4):360-5. PubMed ID: 15812160
[TBL] [Abstract][Full Text] [Related]
45. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
Al-Batran SE; Werner D
Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
[TBL] [Abstract][Full Text] [Related]
46. Metastatic gastric cancer treatment: a little slow but worthy progress.
Kanat O; O'Neil BH
Med Oncol; 2013 Mar; 30(1):464. PubMed ID: 23335104
[TBL] [Abstract][Full Text] [Related]
47. Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
Jia S; Cai J
Anticancer Res; 2016 Mar; 36(3):1111-8. PubMed ID: 26977006
[TBL] [Abstract][Full Text] [Related]
48. Locally advanced and metastatic gastric cancer: current management and new treatment developments.
Field K; Michael M; Leong T
Drugs; 2008; 68(3):299-317. PubMed ID: 18257608
[TBL] [Abstract][Full Text] [Related]
49. Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma.
Anandappa G; Chau I
Hematol Oncol Clin North Am; 2017 Jun; 31(3):529-544. PubMed ID: 28501092
[TBL] [Abstract][Full Text] [Related]
50. HER2-positive gastric cancer.
Boku N
Gastric Cancer; 2014 Jan; 17(1):1-12. PubMed ID: 23563986
[TBL] [Abstract][Full Text] [Related]
51. Gastric cancer: somatic genetics as a guide to therapy.
Zhang XY; Zhang PY
J Med Genet; 2017 May; 54(5):305-312. PubMed ID: 27609016
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
53. Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Hindy JR; Souaid T; Kourie HR; Kattan J
Future Oncol; 2019 May; 15(13):1505-1524. PubMed ID: 30977669
[TBL] [Abstract][Full Text] [Related]
54. Gastric cancer in the era of molecularly targeted agents: current drug development strategies.
Arkenau HT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):855-66. PubMed ID: 19363621
[TBL] [Abstract][Full Text] [Related]
55. Targeted therapy for gastric cancer.
Smyth EC; Cunningham D
Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
[TBL] [Abstract][Full Text] [Related]
56. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
57. Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology.
Smyth EC; Cunningham D
Nat Rev Clin Oncol; 2013 Feb; 10(2):73-4. PubMed ID: 23296114
[No Abstract] [Full Text] [Related]
58. 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer.
Lin HL; Yang MH; Wu CW; Chen PM; Yang YP; Chu YR; Kao CL; Ku HH; Lo JF; Liou JP; Chi CW; Chiou SH
Int J Cancer; 2007 Dec; 121(11):2547-55. PubMed ID: 17680560
[TBL] [Abstract][Full Text] [Related]
59. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions.
Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Pirsalehi A; Safaroghli-Azar A; Zali MR; Bashash D
Eur J Pharmacol; 2021 May; 898():173983. PubMed ID: 33647255
[TBL] [Abstract][Full Text] [Related]
60. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
